Active	Status	Sponsor type	Region	Phase	Filter
6 Active 2 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
He, Qiang
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3	Recruiting	4	466	RoW	Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638	The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd.	Renal Insufficiency, Chronic	10/25	03/26
SCDB, NCT06422845: Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis	Recruiting	N/A	328	RoW	Dissolve AV Peripheral Scoring Drug-coated Balloon, Scoring Drug-coated Balloon	DK Medical Technology (Suzhou) Co., Ltd.	Arteriovenous Fistula Stenosis	07/27	07/27
Xiangmin, Tong
NCT05602792: A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors	Recruiting	1/2	233	RoW	T3011	ImmVira Pharma Co. Ltd	Advanced Solid Tumor, Sarcoma, HNSCC, Breast Cancer, Esophagus Cancer, NSCLC, Non-melanoma Skin Cancer	07/23	01/24
FIH, NCT05707325: Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies	Recruiting	1	30	RoW	engineered red blood cell	Westlake Therapeutics	Cancer, Solid Tumor, Hematologic Malignancy	12/25	07/26
Zongmao, Zhao
NCT05913037: FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas	Recruiting	3	162	RoW	Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group (Group B): Placebo, orally, once daily;	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	Neurofibromatosis 1, Plexiform Neurofibroma, NF1	06/25	06/26